GC Genome Presents Deep Learning AI-Based Early Cancer Diagnosis Research at ESMO

Part of the presentation by GC Genome at the 2022 European Society for Medical Oncology (ESMO) titled ‘Deep Learning-based Multimodal Ensemble Algorithms for Multi-cancer Detection and Classification using cf-WGS’

[Asia Economy Reporter Chunhee Lee] GC Genome announced on the 30th that it participated in the European Society for Medical Oncology (ESMO 2022) held in Paris, France from the 9th to the 13th (local time) and presented research results on early cancer diagnosis using deep learning-based artificial intelligence (AI).

Celebrating its 48th year, the European Society for Medical Oncology is the largest cancer academic conference in Europe and is considered one of the world's top three cancer societies alongside the American Society of Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR). It was held as the first in-person event in three years since the COVID-19 pandemic.

At this conference, GC Genome introduced research results on early cancer diagnosis using deep learning-based AI under the theme "Deep Learning-based Multimodal Ensemble Algorithms for Multi-cancer Detection and Classification using cf-WGS." This test targets major cancer types including breast cancer, colorectal cancer, esophageal cancer, liver cancer, lung cancer, ovarian cancer, and pancreatic cancer. Using AI-based algorithms, it achieved a high accuracy rate of 92.8%.

The research involves obtaining liquid biopsy data through low coverage whole genome sequencing (low coverage WGS) and utilizing both FEMS and RMD AI detection algorithms to enable early diagnosis of multiple cancers.

Eunhae Cho, head of the GC Genome Research Institute, stated, "We expect that by using our technology, which boasts high accuracy based on AI detection algorithms, we can reduce cancer mortality by enabling early diagnosis and treatment of various types of cancer."